Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Approvals Companies Metabolic Disorders

Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait

Based On Positive Phase III Data

  • News

Executive Summary

Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.

You may also be interested in...



Novo Nordisk Has A Plan To Get Wegovy Launch Back On The Rails

The company is targeting revenues of DKK25bn ($3.66bn) from Wegovy for obesity in 2025, with plans to amp up the US launch this year following an initial supply disruption.

Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues

Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.

Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease

Table

View full table

Topics

Related Companies

Tags:
Approvals Companies Metabolic Disorders
Latest Headlines

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

See All
UsernamePublicRestriction

Register

SC145402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By